Systematic review analyzes hormonal effects and sexual behaviors in males undergoing treatment for obesity and erectile dysfunction, suggesting potential benefits with GLP1-RAs.
Present data support the use of GLP1-RAs for improving sexual dysfunction, and its underlying CV problems, in obese patients with ED. A combination of TRT and GLP1-RAs can be considered in selected cases. Data on SGLT2is are too limited to draw final conclusions.
No takes yet. Share an insight, caveat, or question.
Corona et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: